Global Autoimmune Disease Market valued approximately USD 37.81 billion in 2017 is anticipated to grow with a healthy growth rate of more than 3.82% over the forecast period 2018-2025. The Autoimmune Disease Market is continuously growing in global scenario over the coming years. The major driving factor of global Autoimmune Disease market is increasing incidence of chronic diseases and development of novel biomarkers such as Enbrel & Humira. In addition, improvement in regulatory framework, technological enhancements, and growing government assistance are also some other major factors which propelling the growth of the market. However, High treatment cost, poorly trained physicians and emergence of alternative technologies are some major factors which limiting the market growth. Autoimmune disease is a condition in which immune system mistakenly attacks body. These diseases cause dissimilarities in organ functioning, anomalous growth of organs and destruction of vigorous body. These disease are habitually chronic in nature and there is no remedial therapy. The common autoimmune diseases are Type 1 diabetes, Rheumatoid arthritis, Psoriasis/Psoriatic arthritis, Multiple sclerosis, Systemic lupus erythematous (lupus), Inflammatory bowel diseases, Myasthenia gravis, Vasculitis, Celiac disease and so on. Various types of treatment for theses diseases include physical therapy, blood transfusion, recombinant technology, chemo therapy, topical therapy, TNF-a antagonists and Helminthic. The regional analysis of Global Autoimmune Disease Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to increasing investment in R&D and increasing awareness among people related to healthcare. Europe is also estimating to project a major growth in the global Autoimmune Disease market due to increasing disposable income of individuals in the region. Asia-Pacific is also anticipated to exhibit higher growth rate/CAGR over the forecast period 2018-2025 due to improving health infrastructure and increasing aging population. The major market player included in this report are:• Abbott Laboratories• Active Biotech• Eli Lilly• Bristol-Myers Squibb• AstraZeneca plc• Pfizer• Biogen Idec• Lupin Limited• GlaxoSmithKline• Amgen• 4SC• F. Hoffmann-La Roche Ltd.• AutoImmune Inc.• Johnson & Johnson• Bayer

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: